114 related articles for article (PubMed ID: 28529740)
1. Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Loeser H; Waldschmidt D; Kuetting F; Heydt C; Zander T; Plum P; Alakus H; Buettner R; Quaas A
Mol Clin Oncol; 2017 May; 6(5):639-642. PubMed ID: 28529740
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
3. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
4. The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Wong M; Polly P; Liu T
Am J Cancer Res; 2015; 5(9):2823-37. PubMed ID: 26609488
[TBL] [Abstract][Full Text] [Related]
5. The Role of DOT1L in Normal and Malignant Hematopoiesis.
Arnold O; Barbosa K; Deshpande AJ; Zhu N
Front Cell Dev Biol; 2022; 10():917125. PubMed ID: 35712672
[TBL] [Abstract][Full Text] [Related]
6. Utility of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma.
Adsay NV; Dergham ST; Koppitch FC; Dugan MC; Mohamed AN; Vaitkevicius VK; Sarkar FH
Pancreas; 1999 Mar; 18(2):111-6. PubMed ID: 10090407
[TBL] [Abstract][Full Text] [Related]
7. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
Chen J; Park HJ
ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
[TBL] [Abstract][Full Text] [Related]
8. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
9. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
[TBL] [Abstract][Full Text] [Related]
11. Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.
Wang X; Wang H; Xu B; Jiang D; Huang S; Yu H; Wu Z; Wu Q
Am J Transl Res; 2019; 11(2):1145-1153. PubMed ID: 30899413
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
Wang Y; Li L; Zhang B; Xing J; Chen S; Wan W; Song Y; Jiang H; Jiang H; Luo C; Zheng M
J Med Chem; 2017 Mar; 60(5):2026-2036. PubMed ID: 28165739
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Copy Number Variations in Oral Cavity Squamous Cell Carcinoma Reveals a Novel Role for MLLT3 in Cell Invasiveness.
Wang CI; Kao HK; Chen TW; Huang Y; Cheng HW; Yi JS; Hung SY; Wu CS; Lee YS; Chang KP
Oncologist; 2019 Dec; 24(12):e1388-e1400. PubMed ID: 31273053
[TBL] [Abstract][Full Text] [Related]
14. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
15. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
16. Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
Sabatino M; Rotili D; Patsilinakos A; Forgione M; Tomaselli D; Alby F; Arimondo PB; Mai A; Ragno R
J Comput Aided Mol Des; 2018 Mar; 32(3):435-458. PubMed ID: 29335872
[TBL] [Abstract][Full Text] [Related]
17. DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.
Oktyabri D; Ishimura A; Tange S; Terashima M; Suzuki T
Biochimie; 2016 Apr; 123():20-31. PubMed ID: 26783998
[TBL] [Abstract][Full Text] [Related]
18. Histone methyltransferase Dot1L is a coactivator for thyroid hormone receptor during
Wen L; Fu L; Shi YB
FASEB J; 2017 Nov; 31(11):4821-4831. PubMed ID: 28739643
[TBL] [Abstract][Full Text] [Related]
19. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival.
Saxby AJ; Nielsen A; Scarlett CJ; Clarkson A; Morey A; Gill A; Smith RC
Am J Surg Pathol; 2005 Sep; 29(9):1125-34. PubMed ID: 16096400
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
